Effects of Carbidopa and Levodopa Controlled Release Tablets Combined With Levodopa and Benserazide Hydrochloride Tablets on Plasma Hcy and Folic Acid Levels in Patients With Parkinson's Disease
Abstract:Objective To study the effects of Carbidopa and Levodopa Controlled Release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets on plasma homocysteine(Hcy)and folic acid levels in patients with Parkinson's disease(PD). Methods 86 patients with PD who were diagnosed and treated in the hospital were randomized into combined group and control group,43 cases in each group.The control group was treated with oral Levodopa and Benserazide Hydrochloride Tablets,and the combined group was treated with Carbidopa and Levodopa Controlled Release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets.The total response rates and adverse reactions of the two groups were observed.Meanwhile,cognitive function(MMSE and MoCA scores)and plasma folic acid and Hcy levels of the two groups were compared before and after treatment. Results The total response rate of combined group(88.37%)was significantly higher than that of the control group(69.77%)(P<0.05).After treatment,folic acid levels of both groups were significantly increased,and Hcy levels were significantly reduced.Besides,the folic acid level of combined group was significantly higher than that of the control group,and Hcy level was significantly lower than the control group(P<0.05).After treatment,MMSE and MoCA scores of both groups were significantly increased.Besides,the scores of combined group were significantly higher than those of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the 2 groups(13.95% vs.16.28%)(P>0.05). Conclusion Carbidopa and Levodopa Controlled Release Tablets combined with Levodopa and Benserazide Hydrochloride Tablets are effective in treatment of PD,which can significantly improve cognitive function and plasma Hcy,folic acid levels.
牛晓波. 卡左双多巴控释片联合多巴丝肼片对帕金森病患者血浆Hcy、叶酸水平的影响[J]. 哈尔滨医药, 2022, 42(1): 11-13.
Niu Xiaobo. Effects of Carbidopa and Levodopa Controlled Release Tablets Combined With Levodopa and Benserazide Hydrochloride Tablets on Plasma Hcy and Folic Acid Levels in Patients With Parkinson's Disease. journal1, 2022, 42(1): 11-13.